Against Corona, the FOPH relies on patent-protected medicines and ignores cheaper and, above all, much more effective alternatives
by Werner Vontobel
The Federal Office of Public Health (FOPH) knows how to avoid infection with Corona. But as far as the treatment of the disease is concerned, it has learned nothing. It continues to maintain that the new virus can only be combated with a completely new – and thus patent-protected – drug. Of the many patent-protected candidates, however, only Remdesivir from the US pharmaceutical company Gilead remains. The nine "other important drugs" listed on the homepage are painkillers and anaesthetics for the late phase of the disease.